STOCK TITAN

[Form 4] Sensus Healthcare, Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Michael Sardano, who serves as a director and as President and General Counsel of Sensus Healthcare, Inc. (SRTS), reported a purchase of 1,000 shares of the company's common stock on 08/13/2025 at a reported price of $3.37 per share. After the transaction, his reported direct beneficial ownership totaled 116,839 shares. The Form 4 lists the transaction code as "P" and shows the change as an acquisition.

Michael Sardano, membro del consiglio e Presidente e General Counsel di Sensus Healthcare, Inc. (SRTS), ha dichiarato l'acquisto di 1,000 azioni del capitale sociale della società in data 08/13/2025 a un prezzo indicato di $3.37 per azione. Dopo la transazione, la sua partecipazione diretta complessiva è risultata essere di 116,839 azioni. Il Modulo 4 riporta il codice dell'operazione come "P" e indica la variazione come un'acquisizione.

Michael Sardano, que se desempeña como director y como Presidente y Asesor Jurídico General de Sensus Healthcare, Inc. (SRTS), informó la compra de 1,000 acciones de las acciones ordinarias de la compañía el 08/13/2025 a un precio reportado de $3.37 por acción. Tras la operación, su participación directa beneficiaria reportada ascendió a 116,839 acciones. El Formulario 4 registra el código de la transacción como "P" y la clasifica como una adquisición.

Michael Sardano는 이사회 이사이자 Sensus Healthcare, Inc. (SRTS)의 사장 겸 법무총괄로서 회사 보통주 1,000주08/13/2025에 주당 $3.37에 매수했다고 신고했습니다. 거래 후 그의 보고된 직접 실질 소유는 총 116,839주였습니다. Form 4에는 거래 코드가 "P"로 기재되어 있으며 변동은 취득으로 표시되어 있습니다.

Michael Sardano, qui exerce les fonctions d'administrateur ainsi que de président et conseiller juridique principal de Sensus Healthcare, Inc. (SRTS), a déclaré l'achat de 1,000 actions des actions ordinaires de la société le 08/13/2025 à un prix déclaré de $3.37 par action. Après la transaction, sa participation directe bénéficiaire déclarée s'élevait à 116,839 actions. Le formulaire 4 indique le code de la transaction comme "P" et montre que le changement correspond à une acquisition.

Michael Sardano, der als Direktor sowie als Präsident und General Counsel von Sensus Healthcare, Inc. (SRTS) tätig ist, meldete den Kauf von 1,000 Aktien der Stammaktien des Unternehmens am 08/13/2025 zu einem gemeldeten Preis von $3.37 pro Aktie. Nach der Transaktion belief sich sein gemeldeter direkter wirtschaftlicher Besitz auf insgesamt 116,839 Aktien. Auf dem Formular 4 wird der Transaktionscode als "P" angegeben und die Änderung als Erwerb ausgewiesen.

Positive
  • Insider acquisition reported: Michael Sardano acquired 1,000 shares of Sensus Healthcare common stock.
  • Increased disclosed insider ownership: Reported direct beneficial ownership rose to 116,839 shares.
Negative
  • None.

Insights

TL;DR: Officer purchase of 1,000 shares at $3.37 increased direct holdings to 116,839; transaction appears modest with limited market impact.

The Form 4 shows a non-derivative acquisition on 08/13/2025 where Michael Sardano purchased 1,000 common shares at $3.37, raising his direct beneficial ownership to 116,839 shares. The disclosure is straightforward and procedural; there is no additional information on plans or larger trading patterns in the filing to suggest material change in insider exposure.

TL;DR: A director and executive reported a small direct purchase; it increases disclosed insider ownership but is not a material shift.

The filing identifies Sardano as both a director and as President and General Counsel and documents a purchase recorded under transaction code "P." The report updates public records of insider holdings to 116,839 shares. The filing provides clear compliance with Section 16 reporting requirements but contains no governance actions or changes in role.

Michael Sardano, membro del consiglio e Presidente e General Counsel di Sensus Healthcare, Inc. (SRTS), ha dichiarato l'acquisto di 1,000 azioni del capitale sociale della società in data 08/13/2025 a un prezzo indicato di $3.37 per azione. Dopo la transazione, la sua partecipazione diretta complessiva è risultata essere di 116,839 azioni. Il Modulo 4 riporta il codice dell'operazione come "P" e indica la variazione come un'acquisizione.

Michael Sardano, que se desempeña como director y como Presidente y Asesor Jurídico General de Sensus Healthcare, Inc. (SRTS), informó la compra de 1,000 acciones de las acciones ordinarias de la compañía el 08/13/2025 a un precio reportado de $3.37 por acción. Tras la operación, su participación directa beneficiaria reportada ascendió a 116,839 acciones. El Formulario 4 registra el código de la transacción como "P" y la clasifica como una adquisición.

Michael Sardano는 이사회 이사이자 Sensus Healthcare, Inc. (SRTS)의 사장 겸 법무총괄로서 회사 보통주 1,000주08/13/2025에 주당 $3.37에 매수했다고 신고했습니다. 거래 후 그의 보고된 직접 실질 소유는 총 116,839주였습니다. Form 4에는 거래 코드가 "P"로 기재되어 있으며 변동은 취득으로 표시되어 있습니다.

Michael Sardano, qui exerce les fonctions d'administrateur ainsi que de président et conseiller juridique principal de Sensus Healthcare, Inc. (SRTS), a déclaré l'achat de 1,000 actions des actions ordinaires de la société le 08/13/2025 à un prix déclaré de $3.37 par action. Après la transaction, sa participation directe bénéficiaire déclarée s'élevait à 116,839 actions. Le formulaire 4 indique le code de la transaction comme "P" et montre que le changement correspond à une acquisition.

Michael Sardano, der als Direktor sowie als Präsident und General Counsel von Sensus Healthcare, Inc. (SRTS) tätig ist, meldete den Kauf von 1,000 Aktien der Stammaktien des Unternehmens am 08/13/2025 zu einem gemeldeten Preis von $3.37 pro Aktie. Nach der Transaktion belief sich sein gemeldeter direkter wirtschaftlicher Besitz auf insgesamt 116,839 Aktien. Auf dem Formular 4 wird der Transaktionscode als "P" angegeben und die Änderung als Erwerb ausgewiesen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sardano Michael

(Last) (First) (Middle)
851 BROKEN SOUND PARKWAY NW
STE. 215

(Street)
BOCA RATON FL 33487

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sensus Healthcare, Inc. [ SRTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND GENERAL COUNSEL
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/13/2025 P 1,000 A $3.37 116,839 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Michael Sardano 08/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for SRTS?

Michael Sardano, identified as a director and as President and General Counsel of Sensus Healthcare, Inc.

What transaction was reported on the Form 4 for SRTS?

A non-derivative acquisition of 1,000 shares of common stock reported on 08/13/2025.

At what price did the insider transaction for SRTS occur?

The reported price was $3.37 per share.

How many SRTS shares does the reporting person own after the transaction?

The filing reports 116,839 shares beneficially owned following the reported transaction.

What does the transaction code on the Form 4 indicate?

The Form 4 shows transaction code "P" in the table for the reported acquisition.
Sensus Healthcare Inc

NASDAQ:SRTS

SRTS Rankings

SRTS Latest News

SRTS Latest SEC Filings

SRTS Stock Data

53.76M
13.65M
16.97%
26.98%
4.91%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON